Recombinant Human PARP-1 Protein (His Tag)(Active)
SKU: PKSH031294-50
Recombinant Human PARP-1 Protein (His Tag)(Active)
SKU # | PKSH031294 |
Expression Host | Baculovirus-Insect Cells |
Description
Synonyms | ADPRT, ADPRT1, ARTD1, PARP, PARP-1, PPOL, pADPRT-1 |
Species | Human |
Expression Host | Baculovirus-Insect Cells |
Sequence | Met 1-Trp 1014 |
Accession | NP_001609.2 |
Calculated Molecular Weight | 114.5 kDa |
Observed Molecular Weight | 100-110 kDa |
Tag | C-His |
Bio-activity | Immobilized human PARP1 at 10 μg/mL (100 μl/well) can bind biotinylated human HSP70, The EC50 of biotinylated human HSP70 is 0.035 μg/mL. |
Properties
Purity | > 90 % as determined by reducing SDS-PAGE. |
Endotoxin | < 1.0 EU per μg of the protein as determined by the LAL method. |
Storage | Store at < -20°C, stable for 6 months. Please minimize freeze-thaw cycles. |
Shipping | This product is provided as liquid. It is shipped at frozen temperature with blue ice/gel packs. Upon receipt, store it immediately at < -20°C. |
Formulation | Supplied as sterile 20 mM Tris, 300 mM NaCl, 10 % glycerol, 0.5 mM TCEP, 2mM EDTA, pH 7.5. |
Reconstitution | Not Applicable |
Background
Poly (ADP-ribose) polymerase 1(PRAP1), also known as NAD(+) ADP-ribosyltransferase 1(ADPRT), is a chromatin-associated enzyme which modifies various nuclear proteins by poly(ADP-ribosyl)ation. The ADP-D-ribosyl group of NAD+ is transferred to an acceptor carboxyl group on a histone or the enzyme itself, and further ADP-ribosyl groups are transferred to the 2'-position of the terminal adenosine moiety, building up a polymer with an average chain length of 20-30 units. The poly(ADP-ribosyl)ation modification is critical for a wide range of processes, including DNA repair, regulation of chromosome structure, transcriptional regulation, mitosis and apoptosis. PARP1 is demonstrateed to mediate the poly(ADP-ribose) ation of APLF (aprataxin PNK-like factor) and CHFR (checkpoint protein with FHA and RING domains), two representative proteins involved in the DNA damage response and checkpoint regulation. Further, It has been suggested that DNA-dependent protein kinase (DNA-PK), another component of DNA repair, suppresses PARP activity, probably through direct binding and/or sequestration of DNA-ends which serve as an important stimulator for both enzymes. PARP1 inhibitors is thus proposed as a targeted cancer therapy for recombination deficient cancers, such as BRCA2 tumors.